Colorectal Cancer Clinical Trial
Official title:
Oxaliplatin-CPT-11-5-FU-Leucovarin + Bevacizumab and Cetuximab (OCFL-BC) as a Combination Regimen for Systemic Treatment of Advanced Colorectal Carcinoma With Potentially Resectable Liver and/or Lung Metastases. A Phase II Study
Verified date | June 2009 |
Source | National Cancer Institute (NCI) |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Federal Government |
Study type | Interventional |
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, irinotecan, fluorouracil and
leucovorin, work in different ways to stop the growth of tumor cells, either by killing the
cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab and
cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells
to grow and spread. Others find tumor cells and help kill them or carry tumor-killing
substances to them. Giving combination chemotherapy together with monoclonal antibody
therapy may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving combination chemotherapy together
with monoclonal antibody therapy works in treating patients with advanced colorectal cancer
with liver metastases or lung metastases that are potentially removable by surgery.
Status | Active, not recruiting |
Enrollment | 35 |
Est. completion date | |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 70 Years |
Eligibility |
DISEASE CHARACTERISTICS: Inclusion criteria: - Histologically confirmed metastatic colorectal adenocarcinoma - Bidimensionally measurable metastatic disease limited to the liver and considered curatively resectable after response to systemic therapy as assessed by a surgical board - Additional metastatic disease to the lungs consisting of no more than 3 potentially resectable lesions allowed - Must have at least one lesion of 30 mm or less Exclusion criteria: - History or evidence upon physical examination of CNS disease unless adequately treated (e.g., uncontrolled seizure with standard medical therapy or history of stroke) PATIENT CHARACTERISTICS: Inclusion criteria: - Performance status = 1 - Life expectancy > 12 weeks - WBC = 3,000/mm^3 - Platelet count = 100,000/mm^3 - Creatinine 1.25 x upper limit of normal (ULN) - Bilirubin 1.25 x ULN (1.5 x ULN if liver metastasis) - AST and ALT = 3 x ULN (= 5 x ULN if liver metastasis) - Woman and men of childbearing age must use adequate contraception Exclusion criteria: - Pregnancy (positive serum pregnancy test) or lactation - Chronic diarrhea = grade 2 - Other serious illness or medical condition including any of the following: - Unstable cardiac disease requiring treatment - Congestive heart failure or angina pectoris even if medically controlled - Significant arrhythmias - History of significant neurologic or psychiatric disorders including psychotic disorders, dementia, or seizures that would prohibit the understanding and giving of informed consent - Active uncontrolled infection - Severe hypercalcemia - Other serious underlying medical condition that could impair the ability of the patient to participate in the study - Neuropathy > grade 1 of any etiology - Known DPD deficiency - Known severe polyneuropathy - Known allergy to Chinese hamster ovary cell proteins, other recombinant human or humanized antibodies, any excipients of bevacizumab formulation, or any other study drugs - Chronic inflammatory bowel disease - Acute or subacute intestinal occlusion - History of previous arterial thromboembolism - Uncontrolled hypertension - Evidence of bleeding diathesis or coagulopathy - Serious nonhealing wound, ulcer, or bone fracture - History of tumor other than basocellular carcinoma of the skin - Peripheral neuropathy > grade 1 of any origin (e.g., alcohol) - Significant traumatic injury within 28 days prior to study treatment PRIOR CONCURRENT THERAPY: Exclusion criteria: - No prior chemotherapy for metastatic disease - Prior adjuvant chemotherapy permitted if interval since last treatment administration and recurrence is > 6 months - Major surgical procedure or open biopsy within 28 days prior to study treatment or anticipation of the need for major surgical procedure during the course of the study - Treatment in a clinical trial within 30 days prior to study entry - Concurrent treatment with other experimental drugs or other anticancer therapy - Current or recent use (within 10 days prior to study treatment) of full-dose oral or parenteral anticoagulants for therapeutic purposes - Chronic daily treatment with aspirin (> 325 mg/day) |
Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Switzerland | Kantonspital Aarau | Chur | |
Switzerland | Hopital Cantonal Universitaire de Geneve | Geneva | |
Switzerland | Centre Hospitalier Universitaire Vaudois | Lausanne | |
Switzerland | Hopital Regional de Sion-Herens-Conthey | Sion |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Universitaire Vaudois |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pathological complete response rate of lesions of less than or equal to 30 mm in size assessed by pathologic examination in resected specimens | No | ||
Secondary | Response as assessed by NCIC criteria | No | ||
Secondary | Toxicity as assessed by NCIC criteria | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |